1. Home
  2. News
  3. Neuren Pharmaceuticals Limited
  4. DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m

May 9, 2024 at 12:30 AM EDT · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · May 9, 2024 at 12:30 AM EDT · 25 pages · English

On 6ix: 6ix.com/news/daybue-q1-net-sales-usdollar75.9m-full-year-guidance-usdollar370-420m

Neuren Pharmaceuticals Limited on 6ix

Earlier from Neuren Pharmaceuticals

  • Q1 2024 quarterly activity and cash flow reportApr 24, 2024
  • Trofinetide accepted for Priority Review by Health CanadaApr 23, 2024
  • Neuren reports profit of $157 million for 2023Feb 29, 2024
  • Appendix 4E and 2023 full year accountsFeb 29, 2024
  • DAYBUE net sales US$87.1 million in Q4 2023Feb 27, 2024

Later from Neuren Pharmaceuticals

  • Phase 2 trial shows significant improvements in Pitt HopkinsMay 27, 2024
  • Q2 2024 updateAug 7, 2024
  • Phase 2 trial shows significant improvements in AngelmanAug 9, 2024
  • NEU continues PMS P3 preparations after positive FDA meetingOct 6, 2024
  • DAYBUE receives marketing authorization in CanadaOct 16, 2024
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer